Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018;2(3):59-68.
doi: 10.29245/2578-3009/2018/3.1143. Epub 2018 Jun 13.

Implications of the HDAC6-ERK1 feed-forward loop in immunotherapy

Jheng-Yu Wu  1   2 , Niko Moses  1   2 , Wenlong Bai  3 , Xiaohong Mary Zhang  1   2
Affiliations

Implications of the HDAC6-ERK1 feed-forward loop in immunotherapy

Jheng-Yu Wu et al. J Immunol Sci. 2018.

Abstract

The oncogene HDAC6 controls numerous cell processes that are related to tumorigenesis and metastasis, and has recently arisen as a target to treat malignancies. The ERK cascade is a classic pathway driving oncogenesis, and the components of this pathway are either highly mutated in cancers or are vital in cancer's pathological activity. The interactions between these important components of tumor proliferation have been examined, and our research has demonstrated that they regulate each other as evidenced by different posttranslational modifications. Preclinical evidence also supports clinical trials cotargeting these two pathways, which may provide better efficacy than single treatment. Furthermore, HDAC6 and ERK both participate in the regulation of T cell maturation and may have implications on the functions of immune cells. This leads to the possibility of connecting HDAC6 and ERK to immunotherapy. In this review, we summarize the published studies about the interaction of HDAC6 and ERK cascade and their relationship to cancers. We also include the association of HDAC6 and ERK to immune system and discuss the plausibility of linking these to immunotherapy.

Keywords: Cancer; ERK1; HDAC6; Immunotherapy; MAPK; Posttranslational modification.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest All authors certify that they have no conflicts of interest to disclose.

Figures

Figure 1.
Figure 1.
Working models of the interaction between HDAC6 and MAPKs in the T cell and cancer cell. Please see the text for details.
See this image and copyright information in PMC

References

    1. Aldana-Masangkay GI, Sakamoto KM. The role of HDAC6 in cancer. J Biomed Biotechnol. 2011; 2011: 875824. doi:10.1155/2011/875824 - DOI - PMC - PubMed
    1. Samatar AA, Poulikakos PI. Targeting RAS-ERK signalling in cancer: promises and challenges. Nat Rev Drug Discov. 2014; 13: 928–942. doi:10.1038/nrd4281 - DOI - PubMed
    1. Williams KA, Zhang M, Xiang S, et al. Extracellular signal-regulated kinase (ERK) phosphorylates histone deacetylase 6 (HDAC6) at serine 1035 to stimulate cell migration. J Biol Chem. 2013; 288: 33156–33170, doi:10.1074/jbc.M113.472506 - DOI - PMC - PubMed
    1. Deribe YL, Wild P, Chandrashaker A, et al. Regulation of epidermal growth factor receptor trafficking by lysine deacetylase HDAC6. Sci Signal.2009; 2: ra84. doi:10.1126/scisignal.2000576 - DOI - PubMed
    1. Yang MH, Laurent G, Bause AS, et al. HDAC6 and SIRT2 regulate the acetylation state and oncogenic activity of mutant K-RAS. Molecular cancer research : MCR. 2013; 11: 1072–1077. doi:10.1158/1541-7786. - DOI - PMC - PubMed

LinkOut - more resources